COVID-19 Vaccination: From Interesting Agent to the Patient.
COVID-19 Vaccination: From Interesting Agent to the Patient.
复制标题
DOI：
10.3390/vaccines9020120
复制
发表时间：
2021-02-03
期刊：
影响因子：
7.8
通讯作者：
Daou A
中科院分区：
文献类型：
--
作者：
Daou A
新型冠状病毒（COVID-19）疫苗接种正在进行最后阶段的分析和测试。在我们即将取得潜在突破性疫苗接种的情况下，这是一项令人印象深刻的壮举。这将有助于减轻地球仪各地数百万人的压力，帮助恢复世界正常。在这篇综述中，分析了严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的新分支是如何像大流行一样进入世界前列的。本综述将详细介绍COVID-19是什么，它所属的病毒家族以及该病毒家族如何通过攻击重要的人体呼吸器官，循环系统，中枢神经系统和胃肠道来改变身体功能的背景。本综述还研究了新药类似物的过程，从（i）成为有前途的先导化合物到（ii）进入市场，从药物开发和发现阶段到FDA批准和售后研究。这篇综述还讨论了为什么SARS-CoV-2疫苗可能需要比正常情况下少得多的时间才能释放使用的可行理由。
The vaccination for the novel Coronavirus (COVID-19) is undergoing its final stages of analysis and testing. It is an impressive feat under the circumstances that we are on the verge of a potential breakthrough vaccination. This will help reduce the stress for millions of people around the globe, helping to restore worldwide normalcy. In this review, the analysis looks into how the new branch of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) came into the forefront of the world like a pandemic. This review will break down the details of what COVID-19 is, the viral family it belongs to and its background of how this family of viruses alters bodily functions by attacking vital human respiratory organs, the circulatory system, the central nervous system and the gastrointestinal tract. This review also looks at the process a new drug analogue undergoes, from (i) being a promising lead compound to (ii) being released into the market, from the drug development and discovery stage right through to FDA approval and aftermarket research. This review also addresses viable reasoning as to why the SARS-CoV-2 vaccine may have taken much less time than normal in order for it to be released for use.
登录
查看更多内容
影响因子：
6.4
作者：
Guo X;Deng Y;Chen H;Lan J;Wang W;Zou X;Hung T;Lu Z;Tan W
通讯作者：
Tan W
影响因子：
3.5
作者：
DiMasi, JA;Hansen, RW;Grabowski, HG
通讯作者：
Grabowski, HG
影响因子：
--
作者：
Agarwal, Krishna Mohan;Mohapatra, Swati;Mishra, Animesh
通讯作者：
Mishra, Animesh
影响因子：
4.4
作者：
He, YX;Lu, H;Jiang, SB
通讯作者：
Jiang, SB
灭活的SARS-COV疫苗会引起高峰蛋白特异性抗体的高滴度，这些抗体阻断受体结合和病毒的进入。
DOI：
10.1016/j.bbrc.2004.10.052
发表时间：
2004-12-10
影响因子：
3.1
作者：
He Y;Zhou Y;Siddiqui P;Jiang S
通讯作者：
Jiang S